Thera-SAbDab

FIBATUZUMAB

>   Structural Summary
TherapeuticFibatuzumab
TargetEPHA3
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYWMNWVRQAPGQGLEWMGDIYPGSGNTNYDEKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGYYEDFDSWGQGTTVTVSS
Light ChainDIQMTQSPSFLSASVGDRVTITCRASQGIISYLAWYQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental TechnologyPOTELLIGENT Technology;Humaneering Technology
INN Year Proposed2015
INN Year Recommended2017
Companies InvolvedLudwig Institute for Cancer Research, Humanigen, Olivia Newton-John Cancer Research Institute
Conditions Approvedna
Conditions ActiveAcute myeloid leukaemia, Myelodysplastic syndromes, Myelofibrosis, Glioblastoma
Conditions Discontinuedna
NotesFibatuzumab and Ifabotuzumab are the same mAb

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]